Design and evaluation of new antipsoriatic antedrug candidates having 16-en-22-oxa-vitamin D3 structures

Abstract Design, synthesis, and in vitro and in vivo evaluation of a series of antipsoriatic antedrugs having 16-en-22-oxa-vitamin D 3 are described. Among the seven compounds examined, two are promising: ester 5c and amide 5f , both of which exhibit greater potent antiproliferation activity with lessened calcemic activity than the presently prescribed maxacalcitol ( 2 ).